This message contains images. If you don't see images, click here to view.
Advertise in this news brief.



Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit |  Histology Marketplace:     

Home   History   Meeting Calendar   Career Center   Certification   Contact Us    



 




NSH NEWS

IHC Forum features workshop on demystifying CD markers in hematopathology
NSH
July 18
There are hundreds of markers for the cells found in hematopoetic tissues. Hematopathologists use these markers to help differentiate types of cells along with what stage of development they may be in. The intuitive use of these stains in panels can help hematopathologists diagnose and differentiate various hematological diseases. Join us in Tennessee for the eighth annual IHC Forum where this session will review normal bone marrow and lymphoid tissues, discuss the role of Immunohistochemistry in the diagnosis of some hematological diseases along with some technical considerations for working up various antibodies. The differences between T and B-cells and their various subtypes are explored with a concentration on the antibodies used in diagnosis. Quality assurance, staining patterns and emerging antibodies will also be examined. Learn more.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




Individual NSH Webinar on 'Why Do My Medications Cost So Much?'
NSH
July 9
Learn the behind the scenes process in developing a drug for medical use. This Thursday, July 9 at 1 p.m. EST webinar will also share tips on how you can save money on your prescription drugs plus things you can do to choose wellness over sickness. Learn more.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Last chance to participate in ASCP 2015 wage survey
American Society for Clinical Pathology
The ASCP is conducting its wage survey of laboratory professionals in the field. The wage survey will remain open until midnight PDT, June 28.

As always, the ASCP has taken special measures to ensure survey takers privacy and the privacy of your laboratory. All responses are strictly confidential. No individual level data will be revealed, and in the final survey report, all information will be aggregated. This survey takes approximately 15 minutes to complete. There is a "back" button at the bottom of the page which will allow you to go back to the previous question to change your answer if necessary. Click here to take the survey.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


PRODUCT SHOWCASE
  GBI Cost Effective Products

GBI Labs produces the largest selection of secondary detection kits, from single to multiple detection kits, with wide range host species. We provide FREE samples to 1st time users. Staining with our kits results in similar or better sensitivity than other detection kits on the market with 20%-30% cost less.
 


TOP STORIES


Data for 100,000 Californians powering disease research
Health Data Management
The first published research for a precision medicine project based on electronic health records and genetic data from more than 100,000 Californians is proving to be a powerful tool. The research is pinpointing genetic variants linked to prostate cancer, allergies, glaucoma, macular degeneration, diabetes and high cholesterol.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The massive waste happening in mosquito-borne disease research
The Conversation
Nearly two-thirds of the world's population are at risk from vector-borne diseases — diseases transmitted by bites from infected insects and ticks. The most deadly of these is malaria which causes nearly 600,000 deaths each year, mostly in young children in Africa. Much has been done to tackle this disease, but research published in Trends in Parasitology suggests that the poorly designed field trials are causing a massive waste of financial resources.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Mobile data collection's role in precision medicine and the clinical trial of the future
MobiHealthNews
In 2011, Pfizer announced a novel clinical trial that would be fully remote, with every aspect of the trial being handled either online, over the phone or by mail. But that trial was cancelled due to a failure to recruit enough participants, and a promised mulligan never emerged. Craig Lipset, Pfizer's head of Clinical Innovation, said at the BIO conference in Philadelphia recently that since 2011, Pfizer has incorporated many successful facets of that trial into its ongoing efforts — and has put the failed aspects out there for other companies to learn from.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Missed an issue of Under The Microscope? Click here to visit the Under The Microscope archive page.


UT System's clinical trials network can help get more effective drugs to patients faster
News-Medical.Net
The University of Texas System has launched a groundbreaking clinical trials network to ensure drugs and therapies developed by researchers at UT institutions get to patients faster and are effective.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  Hassle Free Block Storage Cabinet

Avantik Biogroup is proud to introduce another Customer Requested Quality Innovation for Histology...the Avantik Biogroup Block Storage Cabinet! We introduced Hassle-Free Drawer Technology with Interlocking Stackability and More Clearance between the top of the blocks and the drawers to achieve the industry's first Jam-Free, Hassle-Free Block Storage Cabinet!
 


IN THE NEWS


Clinical trial for experimental Ebola drug halted
Modern Healthcare
Clinical drug trials of an experimental treatment for Ebola have stopped after it was found unlikely to be effective. Health officials have been looking to abate the effects of the virus strain that has ravaged West Africa for more than a year. Recently, Vancouver-based Tekmira Pharmaceuticals Corp. announced it was no longer enrolling patients into its Phase II clinical trial of its experimental drug TKM-Ebola-Guinea, stating that "continuing enrollment was not likely to demonstrate an overall therapeutic benefit."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


How to develop validated HPLC methods
Lab Manager
Michael Rummel has held the position of chief operating officer at InSource Diagnostics, an independent laboratory that focuses on medication monitoring and compliance testing, for several years. In his current position at InSource Diagnostics, he has become intimately involved in clinical workflows, regulatory requirements and enforcement of strict quality control/quality assurance for LC/MS clinical assays. He has future aspirations of leveraging his knowledge to help develop a next generation of clinical diagnostics assays that involve less invasive sampling techniques and greater accessibility for patients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Creating added value from clinical pathology lab testing produced improved outcomes at University of Mississippi Medical Center and Broward Health
Dark Daily
One big challenge facing medical laboratories and anatomic pathology groups in the United States today is the need to transition from a transaction-based business model (increasing specimen volume leads to increasing revenue) to a value-based business model (helping providers improve their use of clinical laboratory tests in ways that measurably improve patient outcomes while controlling or reducing the cost of care.) Two trends reinforce the need for clinical laboratories to craft strategies to develop new ways to add value to lab testing services.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


When inflammation occurs, kidneys work to protect themselves, researchers find
Medical College of Georgia via Medical Xpress
In an apparent effort to help themselves, inflamed kidney cells produce one of the same inflammation-suppressing enzymes fetuses use to survive, researchers report. Inflammation is a major culprit in most kidney disease — from rare conditions, such as Goodpasture syndrome, where the immune system starts producing antibodies against kidney collagen to an infection with hepatitis C to the slow, persistent pounding of hypertension, said Dr. Tracy L. McGaha, immunologist in the Department of Medicine at the Medical College of Georgia at Georgia Regents University.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Clinical trials launching to combat advanced skin cancer
Idaho Statesman
Mayo Clinic and the Translational Genomics Research Institute are helping launch a national clinical trial that will apply the latest in precision medicine to treat advanced melanoma skin cancer. The study leverages advances in genomics, informatics and health information technology, yielding more precise medical treatments for patients with this devastating disease
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    The introverted manager (Lab Manager)
NIH's drug lab is shut down after FDA finds quality failures (Bloomberg)
Scientists identify protein that sustains heart function into old age (Johns Hopkins University School of Medicine via Medical Xpress)

Don't be left behind. Click here to see what else you missed.


 

Under the Microscope
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Ashley Whipple, Senior Content Editor, 469.420.2642   
Contribute news

This edition of Under the Microscope was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
June 17, 2015
June 10, 2015
June 3, 2015
May 28, 2015 blast



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063